Reacta Healthcare
PrivateLast Round
Grant
Apr 27, 2022
Total Funding Raised
$1.54M
Company Overview
Reacta Healthcare operates in Healthcare & Life Sciences and is based in Deeside. Its latest recorded funding round was a Grant round in April 2022.
Reacta Healthcare is a life sciences company that develops and manufactures pharmaceutical-grade oral food challenge products for use in food allergy clinical trials.
Sector
Healthcare & Life Sciences
Verticals
Clinical Trials, Biotechnology, Pharma Supply Chain
Business Model
B2B
Customer Profile
Services & Consulting, Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Reacta Healthcare Comparables
Compare Reacta Healthcare with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Stallergenes Greer | 53% | |
| Thermo Fisher Scientific Inc. | 51% | |
| AllerGenis | 48% |
For institutional investors. Book with your work email.
Reacta Healthcare Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Apr 27, 2022 | ||||
| VC Round | Jul 14, 2021 | ||||
| VC Round | Apr 21, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Reacta Healthcare Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Praetura Ventures | VC Round |
| Innovate UK | Grant |
| Perscitus LLP | VC Round |
| Acceleris Capital | VC Round |
| Development Bank of Wales | Seed, VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 2, 2026
Open job postings surged to 29 roles (36% of headcount, 3.3x the trailing average)
- Apr 20, 2026
Monthly visitors increased 8908% to 6.6K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- recognized_asSep 16, 2026
Great Place To Work(R) UK recognizes Reacta Healthcare as one of the UK's Best Workplaces in BioPharma(TM), based on its Trust Index(TM) survey of UK-based BioPharma employees, on Sep 16th '26 in United Kingdom.
- hiresAug 10, 2026
Reacta Healthcare appoints Iedena Lima as Head of Research and Development and member of its Senior Leadership Team in United Kingdom on Aug 10th '26.
For institutional investors. Book with your work email.
Reacta Healthcare Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Reacta Healthcare's valuation, stock price, and market status.
Is Reacta Healthcare a public or private company?
Reacta Healthcare is a private company.
What is the current stock price of Reacta Healthcare?
Reacta Healthcare is a private company, so its shares have no public market price. Caplight tracks Reacta Healthcare's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Reacta Healthcare worth (valuation)?
Valuation information for Reacta Healthcare is not publicly available.
Can I buy Reacta Healthcare stock?
Reacta Healthcare shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Reacta Healthcare's last funding round?
Reacta Healthcare's most recent funding round was Grant on April 27, 2022.
Who are the main investors in Reacta Healthcare?
Key investors in Reacta Healthcare include Praetura Ventures.
Will Reacta Healthcare IPO soon?
No public IPO plans have been announced for Reacta Healthcare.
How can I track Reacta Healthcare secondary market activity?
Caplight tracks bids, offers, and trades in Reacta Healthcare's shares on secondary markets.